In a recent paper, the development of MBP134AF, a pan-ebolavirus monoclonal antibody comprising two broadly neutralising human antibodies (bNAbs), was found to be effective and potent against antigenically diverse ebolaviruses. In this study, the authors found that MBP134AF also fully protects ferrets against lethal Ebolavirus (EBOV), Sudan virus (SUDV) and Bundibugyo virus (BDBV) infections. They also found that a single 25 mg/kg dose is sufficient to protect non-human primates against all three of these viruses. Therefore this monoclonal antibody may advance to human trials.
Read more here